As in previous years, the consensus group to consider the use of biological agents in the treatment of rheumatic diseases met during the 11th Annual Workshop on Advances in Targeted Therapies. The group consisted of rheumatologists from a number of universities among the continents of Europe, North America, South America, Australia and Asia.
Pharmaceutical industry support was obtained from a number of companies for the annual workshop itself but these companies had no part in the decisions about the specific programme or about the academic participants at this conference. Representatives of the supporting sponsors participated in the initial working groups to supply factual information. The sponsors did not participate in the drafting of the consensus statement.
This consensus was prepared from the perspective of the treating physician.
In view of the new data for abatacept, 1 B-cellspecific agents, 2 interleukin 1 receptor antagonists (IL1ra), 3 tocilizumab (TCZ), 4 and tumour necrosis factor a (TNFa) blocking agents, 5 an update of the previous consensus statement is appropriate. The consensus statement is annotated to document the credibility of the data supporting it as much as possible. This annotation is that of Shekelle et al and is described in the appendix. 6 We have modified the Shekelle annotation by designating all abstracts as ''category D evidence'', whether they describe well-controlled trials or not, as details of the study were often not available in the abstracts. Further, the number of possible references has become so large that reviews are sometimes included; if they contain category A references, they will be referred to as category A evidence.
The rheumatologists and bioscientists who attended the consensus conference were from 23 countries, and were selected for their expertise in the use of biological agents for the treatment of rheumatic diseases. The number of attendees and participants was limited so that not everyone who might have been interested could be invited. All participants reviewed a draft document developed by the coauthors, based on a review of all relevant clinical published articles relating to abatacept 1 and rituximab (B-cell specific therapy), 2 as well as IL1 blocking agents, 3 TCZ 4 and TNF blocking agents. The draft was discussed in small working groups. The revisions suggested by each group were discussed by all participants in a final open session and this led to a final document, representing this updated consensus statement.
It is hoped that this statement, which is based on the best evidence available at this time, and is modified by expert opinion, will facilitate the optimal use of these agents for patients with conditions approved by the FDA or EMEA (European Medicines Agency) for clinical use. Extensive tables of the use of these agents in non-registered uses are included as appendices, to help experienced doctors to use these drugs in exceptional (''off-label'') circumstances.
GENERAL STATEMENTS
Individual patients differ in the clinical expression and aggressiveness of their disease, its concomitant structural damage, the effect of their disease on their quality of life (QoL) and the symptoms and signs engendered by their disease. They also differ in their risk for, and expression of, side effects to drugs. All these factors must be examined when considering biological treatment for a patient, as must the toxicity of previous and/or alternative disease-modifying antirheumatic drug (DMARD) use.
As increasing evidence has accumulated on the efficacy and clinical use of biological agents for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS), these diseases will be discussed separately from rheumatoid arthritis (RA). Adverse reactions unless disease-specific, however, will remain combined for all indications.
In general, in RA, when measuring response to treatment or when following up patients over time, the American College of Rheumatology (ACR) response criteria (as a combined index) should not be used in a clinical practice setting to monitor individual response, although some validated measure of response (such as those which follow) should be employed (category B evidence 2 7 ). Validated quantitative measures such as the Disease Activity Score (DAS), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), RAPID Health Assessment Questionnaire disability index (HAQ-DI), visual analogue scales (VAS) or Likert scales of global response or pain by the patient or global response by the doctor, other validated measures of pain for individual patient care, joint tenderness and/or swelling counts, and laboratory data may all be used and may be appropriate measures for individual patients. The doctor should evaluate a patient's response using one of the above instruments to determine the patient's status and change.
For PsA, measures of response such as joint tenderness and swelling, global and pain response measures, functional indices and acute phase reactants have been used. [1] [2] [3] For AS, measures such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Functional Index (BASFI) have been used in clinical trials but have not been validated for routine clinical practice (category C evidence 8 ). Clinical measures such as joint tenderness and swelling, spinal motion, global and pain response measures, functional indices and acute phase reactants have been used and are validated.
The appropriate use of biological agents will require doctors experienced in the diagnosis, treatment and assessment of RA, PsA, AS and other rheumatic diseases who are aware of longterm observations of efficacy and toxicity, including cohort studies and data from registries. Because biological agents have adverse effects, patients or their representatives should be provided with information about potential risks and benefits so that they may give informed consent for treatment.
ABATACEPT
One agent which modulates T-cell activation (abatacept) has been approved in the United States and Europe.
Indications

Rheumatoid arthritis
Abatacept is approved in North America for use alone or with background DMARDs for treatment of moderate to severe adult RA or polyarticular JIA.
Abatacept is recommended for treatment of active RA as monotherapy or with DMARDs after an adequate trial of methotrexate (MTX) or another effective DMARD (in the USA). Abatacept has been approved by the EMEA for active RA after an inadequate response to a non-biological DMARD and includes a failure of at least one TNFa blocking agent.
Abatacept may be administered at the time when the next dose of the TNFa blocking agent would normally be given (category C evidence 9 ). Abatacept has been used with MTX and other DMARDs (category A evidence [10] [11] [12] [13] [14] [15] ).
Clinical use Dosing and time to response
Abatacept is administered as intravenous infusions of approximately 8 or 10 mg/kg (500 mg for weights less than 60 kg; 750 mg for weights of 60-100 kg and 1000 mg for weights over 100 kg) at 0, 2, 4 weeks and then monthly (FDA product label). Abatacept decreases signs and symptoms of RA and improves physical function in adult patients with moderately to severely active RA who have had an inadequate response to one or more DMARDs such as MTX or TNF blocking agents (category A evidence 10 11 16 17 [22] [23] [24] [25] [26] [27] ).
Persistence and degree of response
Some patients continue to respond to abatacept for up to 3 (TNF-incomplete responders (TNF-IR)) to 5 years (MTXincomplete responders (MTX-IR)) in long-term, open-label extension studies (category C evidence 12 14 ).
Comparison with TNFa blocking agents
The efficacy of abatacept was similar to infliximab at 3 mg/kg with numerically fewer serious adverse events in the abatacepttreated patients (category A evidence 28 ).
Structural changes
Abatacept in combination with MTX slows radiographic progression in RA in MTX-IR (category A, B, C evidence 14 25 [29] [30] [31] ).
Safety
Patients with chronic obstructive pulmonary disease (COPD) treated with abatacept had more serious lower respiratory tract infections than patients treated with placebo; therefore its use in patients with RA and COPD should be undertaken with caution. 
Autoimmune disease
Infections Tuberculosis
All patients in abatacept phase 3 trials were screened for tuberculosis (TB) with a tuberculin skin test but were still included if the screen was positive and they were treated for latent TB. There are cases of TB observed in the clinical trial programme (category C, D evidence 33 34 ). The risk for reactivation of latent TB or for developing new TB when using abatacept is unknown. Until the risk is known, it is appropriate to screen patients considered for abatacept treatment for TB according to local practice.
Serious infections
In comparison with placebo in clinical trials the incidence of serious infections with abatacept was increased in one trial but not in a meta-analysis (category A evidence 34 35 ). In a review of clinical trial data, the incidence of hospitalisations for infections remained stable for up to 3 years and the incidence did not differ in the long-term extension as compared with the blinded phase of clinical trials. As with the other such trials, the uncontrolled cohort design with observed data limits the generalisability of these data (category C evidence 34 ). In combination with other biological agents, the rate of serious infections is 4.4% (vs 1.5% in controls; category C evidence 15 ) The use of abatacept with TNF blocking agents is not recommended, as an increased incidence of serious infections was noted when the combination was used (category A evidence 36 37 ). There are no data about the combination of abatacept and rituximab.
2009 Update: There was a decreased response to influenza, tetanus and pneumococcal vaccinations when using abatacept in healthy volunteers (category C evidence 38 ). Influenza and pneumococcal vaccinations in patients with RA receiving abatacept were reduced as in previous reports of patients with RA receiving MTX (category D evidence 39 ). Owing to theoretical concerns, live vaccines should not be given while a patient is receiving abatacept or within 3 months of using abatacept.
Malignancies
There has been one case of a lymphoma occurring in a doubleblind trial with abatacept versus none in the placebo group; four additional cases occurred in the open-label extension (cumulatively 5/4134 patient-years) while an epidemiological overview showed no increase (category B, D evidence 40 41 ). While this number is consistent with that expected from large RA cohorts, continuing surveillance is necessary.
2009 Update:
In a comparison of abatacept clinical trial data with national registries, no increased rates of lymphoma, lung, breast, colorectal or total malignancies were found, although the control populations were not completely comparable (category D evidence 40 ). Epidemiological experience in six RA cohorts shows no increased rate of solid malignancies compared with the RA cohorts (category D evidence 41 ), but continued monitoring is necessary.
Summary
Abatacept is effective for the treatment of moderate to severe RA in patients who have had an inadequate response to MTX or to at least one TNFa blocking agent. The safety of abatacept is still being defined, although caution is advised when using abatacept in the presence of COPD.
RITUXIMAB (RTX) B-CELL THERAPY
Rituximab is a chimeric anti-CD20 monoclonal antibody which was approved in 1997 for treatment of indolent CD20, B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia. More than 1 000 000 patient exposures (usually four infusions per patient) have been documented over 9 years in postmarketing surveillance of these patients with NHL. A consensus statement on the use of rituximab in patients with RA has been published (category D evidence 42 ). In a retrospective non-randomised open-label study, patients for whom one or more TNF antagonists had been ineffective were switched to RTX and this drug was more effective than using another TNF inhibitor.
Indications
Rheumatoid arthritis
74
Repeat dosing studies revealed that in MTX-IR patients, escalation from 500 mg per infusion to 1000 mg in the second course was equivalent to two courses of 500 mg or 1000 mg (unpublished data) but in TNF-IR patients two courses of 1000 mg 62 appear to be more efficacious than two courses of 500 mg 62 (category C evidence 75 ). Open-label extension studies of up to 6 years showed continued response (category D evidence 76 ). DMARDs other than methotrexate can be used with rituximab (category D, evidence 73 ).
Structural changes
There are data indicating that rituximab can slow radiographic progression in patients who have had an inadequate response to one or more TNF blockers (category A evidence 77 ). ) . This suggests that the timing of re-treatment should be based on disease activity rather than repletion of peripheral B-cell levels.
Vaccination
Since rituximab causes B-cell depletion, it is recommended that any vaccinations required by the patient, such as those to prevent pneumonia and influenza, should be given before starting treatment. While receiving treatment, appropriate vaccination (such as against influenza) should be given when indicated, although the responses have been shown to be submaximal (category A evidence 89 ). 2009 Update: In a controlled trial, rituximab significantly decreased the immune response to neoantigen, (KLH), and pneumococcus, whereas DTH responses and responses to tetanus were unchanged (category A evidence 90 ). Until further data are available, the use of live attenuated vaccines should only be given before the use of rituximab.
Infusion reactions
The most widespread adverse events are infusion reactions, which are most common with the first infusion of each course (up to 35%) and are reduced with the second and subsequent infusion (about 10%). Intravenous corticosteroids were shown to reduce the incidence and severity of infusion reactions by about 30% without changing efficacy (category A, C and D evidence 43 44 46 48 52-55 57 ). Rare anaphylactoid reactions have occurred when rituximab is used (category C evidence 91 ).
Malignancies
There is no evidence that rituximab is associated with an increased incidence of solid tumours in RA. Nevertheless, vigilance for the occurrence of solid malignancies remains warranted during treatment with rituximab (category B evidence 76 ).
Neurological syndromes
Cases of progressive multifocal leucoencephalopathy (PML) have been seen in patients with systemic rheumatic diseases with and without rituximab treatment (FDA communication). Two cases of PML in patients with RA treated with rituximab have been reported. The causal relationship between PML and rituximab remains unclear.
Skin reactions
Rare reports of psoriasis, including severe cases, have been reported in patients with RA, SLE and NHL after rituximab treatment (category D evidence 92 93 ). The causative role of rituximab in this circumstance remains unknown.
Summary
Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or who have used one or more TNFa blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.
IL1 BLOCKING AGENTS
One IL1 blocking agent, anakinra (IL1ra), has been approved for use in RA. A second IL1 inhibitor, rilonacept (IL1 Trap), has recently been approved for use in cryopyrin-associated periodic syndromes (CAPS; category A, C evidence 94-96 ).
Indications
Rheumatoid arthritis
Anakinra may be used for the treatment of active RA, alone or in combination with MTX, at a dose of 100 mg/day subcutaneously (category A evidence [96] [97] [98] [99] [100] [101] ). In Europe, the anakinra label requires prescription in combination with MTX. Anakinra is recommended for the treatment of active RA after an adequate trial of non-biological DMARDs or with other DMARDs (category A evidence 98 99 ; category C evidence 102 ). No trials of anakinra as the first DMARD prescribed for patients with early RA have been published.
Update:
Cryopyrin-associated periodic syndromes Anakinra and rilonacept have clinical benefits in relatively small numbers of patients with CAPS, including familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease, which are characterised by mutations in the NALP3 gene (category A, C evidence 95 102 104 ). Successful treatment with anakinra in children with idiopathic recurrent pericarditis suggested that this disorder may be a previously unrecognised autoinflammatory syndrome (category D evidence 105 ).A placebo-controlled randomised clinical trial has highlighted the clinical efficacy of rilonacept in patients with CAPS 7 (category A evidence 95 ).
Clinical use Timing of response
Anakinra can lead to significant improvement in symptoms, signs and/or laboratory parameters of RA within 16 weeks, and can slow the rate of radiographic progression (category A evidence 96-98 100 ). If improvement is not seen by 16 weeks, the continued use of anakinra should be reconsidered.
Comparison with TNFa blocking agents
Despite the lack of head-to-head comparisons, anakinra is considered to be less effective than TNF blocking agents (category B evidence 106 ). Clinical trials of patients for whom anti-TNF therapy has failed showed variable responses to anakinra (category C evidence 101 ).
Infections Tuberculosis
To date, there is no indication that use of anakinra is associated with an increased incidence of TB (category D evidence 107 ).
Bacterial infections
The frequency of serious bacterial infections was increased in patients receiving anakinra, and its incidence is higher than in patients with RA using non-biological DMARDs. The increased incidence of infection was greatest in patients who were also receiving corticosteroids (category A evidence 99 ; category C evidence 107 ). Patients should not start or continue anakinra if a serious infection is present (category A evidence 4 109-111 ; category C evidence 107 ; category D evidence 112 ). Treatment with anakinra in such patients should only be resumed if the infection has been adequately treated.
When anakinra was used in combination with etanercept, there was no increase in efficacy. However, an increase in the incidence of serious infection was seen in comparison with either compound used as monotherapy. Therefore, the combination of anakinra and etanercept should not be prescribed (category A evidence 113 ).
Vaccinations
In one controlled trial, anakinra did not inhibit antitetanus antibody response (category D evidence 114 ).
Injection site reactions
A dose-related incidence of injection site reactions, affecting up to 70% of patients, has been reported with the use of anakinra. These reactions often do not require treatment and seem to moderate with continued use in most patients (category A evidence [96] [97] [98] ).
Summary
Anakinra and rilonacept are effective in the treatment of CAPS. It is also effective in the treatment of JIA, adult Still's disease and RA, but its position in the therapeutic algorithm of RA is unclear.
Ankylosing spondylitis and psoriatic arthritis
Anakinra has been evaluated in two open-label studies of AS, but without consistent evidence of efficacy. 115 116 Anakinra did not demonstrate clinical efficacy in PsA. 43 
Crystal-associated arthropathies
There are anecdotal reports of clinical efficacy after treatment with anakinra in patients with intractable gout 116a and pseudogout 116b .
Other arthropathies
Treatment with intra-articular anakinra was evaluated in a randomised clinical trial of patients with osteoarthritis.
117-138
Treatment was well tolerated but no improvements were seen compared with placebo. There are anecdotal reports concerning the use of anakinra in patients with systemic lupus erythematosus, Behçet disease and relapsing polychondritis.
TOCILIZUMAB
Tocilizumab is a humanised anti-IL6 receptor monoclonal antibody (category A/D evidence [137] [138] [139] [140] [141] [142] ).
Indications
Tocilizumab has been approved in the European Union and a number of other countries in combination with MTX or as monotherapy for the treatment of moderate-to-severe active RA in adults who are incomplete responders (owing to adverse effects or lack of response) to DMARDs or TNF blocking agents (category A, D evidence 137-142 144 ). In Japan and India tocilizumab has also been approved for polyarticular JIA, systemic-onset JIA and multicentric Castleman's disease (category A, D evidence [145] [146] [147] [148] ). 
Clinical use
Dosing
Tocilizumab is administered intravenously monthly in a dose of 4 or 8 mg/kg (category A, D [137] [138] [139] [140] [141] [142] ). In combination with MTX or other DMARDs it can be used at 4 or 8 mg/kg, although 4 mg/ kg monotherapy was less effective in DMARD incomplete responders (category A, D evidence 137-140 142 ).
Timing of response
Onset of response occurs between 2-4 weeks in some patients but it may evolve for up to 24 weeks. (category A, D evidence 2 ).
Juvenile idiopathic arthritis
Tocilizumab improves systemic signs and symptoms in patients with systemic-onset JIA in a dose of 8 mg/kg every 2 weeks (category A evidence 147 ) and in polyarticular JIA (category A, D evidence 144 ).
Comparison with TNF blocking agents
Tocilizumab has not been compared directly with TNF blocking agents. It can be used after failure of one or more TNF blocking agents (category A evidence 149 ).
Structural changes
Tocilizumab inhibits radiographic progression in patients who have had an inadequate response to MTX or other DMARDs (category A, D evidence 140 142 ), and it slows radiographic progression as monotherapy (category A evidence 144 ).
Safety
Cardiovascular end points and lipid levels
The overall long-term effect of TCZ on cardiovascular outcomes is at present not known. Increases in mean fasting plasma lipid levels were seen in TCZ-treated patients relative to controls, including total cholesterol, low-density lipoprotein and triglycerides with smaller increases in high-density lipoprotein (category A, D evidence [150] [151] [152] [153] . This change usually occurs early after a dose and is transient. Complete blood counts should be monitored regularly. In one study, there was an accompanying increase in infections but this was not seen in most studies (category A, D evidence 155 156 ).
Increases in hepatic aminotranferase and bilirubin
Increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) occurred with similar frequency with TCZ monotherapy compared with MTX alone (category A evidence [157] [158] [159] ). In combination with MTX, increases are more common.
2009 Update: Increases of bilirubin, mostly indirect, occur separately and are not associated with hepatic dysfunction. Liver function should be monitored regularly. Guidelines consistent with those for MTX for the management of TCZrelated laboratory abnormalities have been included in the EMEA package. 144 No instances of TCZ-induced hepatic failure or liver damage have been documented (category A, D evidence 137-142 156 158 ).
Infections
Bacterial Infections
The incidence of serious infection at rates up to 4.6/100 patientyears was stable in a median follow-up of 1.5 years (category D evidence 152 ). TCZ should not be given in the presence of serious or opportunistic infections (category D evidence 140 ). As with other biological agents careful observation for bacterial infections is necessary (category A, D evidence 134-142 152 154 155 ).
Tuberculosis and opportunistic infections
Patients with active tuberculosis and atypical mycobacterial infections were excluded in all studies, so there are insufficient data provide information about the need for TB screening before initiating TCZ treatment. Local practice for TB screening should be observed. Cases of TB have been seen in patients taking TCZ (EMEA; category D evidence 140 ).
Viral infections
Cases of localised H zoster infection have occurred in clinical trials, but it is not clear whether H zoster is increased in association with TCZ (category D evidence 139 140 ).
Vaccination
Safety and response to vaccinations were evaluated in patients with RA receiving TCZ. Most patients could be effectively immunised with influenza vaccine (category D evidence ). As for the other biological agents, live vaccines should not be given while patients are receiving TCZ (category A, D evidence 140 156 157 ).
Infusion-related events
Serious infusion reactions during/after treatment with TCZ are uncommon (category A, D 160 ).
Malignancies
There is no evidence that TCZ treatment is associated with an increased incidence of malignancies in patients with RA (category A, D evidence 137-142 144-146 148 150 ). Systematic safety surveillance should be performed during TCZ treatment, similar to requirements for other biological agents.
Summary
Tocilizumab is effective in patients with an inadequate response to MTX for whom conventional DMARDs have failed or who have had one or more TNFa inhibitors. It is also effective as monotherapy and in one study was better than MTX. The safety of TCZ requires further evaluation in long-term extension studies and surveillance databases.
Research agenda
c Studies are needed to determine whether immunisation with vaccinations should be carried out in adults before initiation of TCZ.
c Studies are needed with respect to the incidence of TB and opportunistic infections when using TCZ.
c Continued follow-up is necessary to ascertain relationships between TCZ and cardiovascular events, hepatic failure, viral illness (including H zoster) and malignancy.
TNF BLOCKING AGENTS
TNF blocking agents differ in composition, precise mechanism of action, pharmacokinetics and biopharmaceutical properties, but this document emphasises areas of commonality. Studies that have clearly differentiated between compounds will be discussed, where appropriate.
Indications
Rheumatoid arthritis
In most patients, TNFa blockers are used in conjunction with another DMARD, usually MTX. TNFa blocking agents have also been used successfully with other DMARDs, including sulfasalazine and leflunomide. 163 167 ). Adalimumab and etanercept are both approved as monotherapy for RA. Infliximab is only approved for use with MTX in RA. However, observational data indicate that infliximab, too, is sometimes used as monotherapy (category C evidence [169] [170] [171] ). The combination of a TNFa blocking agent and MTX yields better results for RA than monotherapy, particularly with respect to excellent clinical responses (ACR 70, remission) and radiological outcomes (category A evidence [172] [173] [174] 
Psoriatic arthritis
Based on the demonstration of control of signs and symptoms of joint and skin disease, improvement of function, QoL and inhibition of structural damage, the available TNFa blocking agents (adalimumab, etanercept, golimumab and infliximab) have been widely approved for the treatment of patients with PsA for whom conventional treatments have produced an inadequate response. Efficacy has been demonstrated both with monotherapy and with background MTX (category A evidence 75 176-186 ).
Ankylosing spondylitis
Adalimumab, etanercept, golimumab and infliximab have been widely approved for the treatment of active AS that is refractory to conventional treatments. In clinical trials, the efficacy of these TNFa blocking agents improved signs and symptoms, function and QoL as monotherapy as well as with concomitant second-line agents, including sulfasalazine or MTX (category A, B evidence 187 187-193 ; category D evidence 192 ). There is no evidence that combination therapy with conventional DMARDs is better than monotherapy with TNF blocking agents.
Juvenile idiopathic arthritis
Etanercept and adalimumab have been approved for JIA with a polyarticular course (FDA: >2 years for etanercept: >4 years for adalimumab; EMEA: age 13-17 years for both) (category A evidence 111 194-196 ; FDA and EMEA approvals). Infliximab was beneficial at 6 mg/kg in polyarticular JIA (category A evidence 194 195 ). Appendix 3 provides evidence supporting the use of TNFa blocking agents in other rheumatic diseases or those with prominent rheumatic manifestations.
Clinical use
Rheumatoid arthritis Dosing and time to response
Increasing the dose or reducing the dosing intervals of infliximab and adalimumab may provide additional benefit in RA, whereas increased doses of etanercept have increased benefit on a group level (category A evidence 197 198 ). The addition or substitution of other DMARDs may increase efficacy in some patients.
TNFa blocking agents, when administered up to the maximum approved dosing regimens for RA and polyarticular JIA may elicit response in 2-4 weeks in some patients. They usually lead to significant, documentable improvement in symptoms, signs and/or laboratory parameters within 12-24 weeks (category A, B evidence 117 199-206 2009 Update: For remission or low disease activity, anecdotal studies indicate that lowering the dose may be successful without loss of effect (category C evidence 207 ).
Comparing TNFa blocking agents
There is no evidence that any one TNFa blocking agent should be used before another one can be tried. There is also no evidence that any TNF blocking agent is more effective than any other in RA (category A and B evidence 17 26 27 51 ).
Persistence and degree of response
In long-term observational studies, some patients continue to respond for up to 10 years (category C evidence 208 ). Loss of response to a TNF blocking agent can occur. Failure to respond to one TNF blocking agent does not preclude response to another (category B, D evidence 209 210 ). Patients have been switched successfully from one TNF blocking agent to another.
2009 Update: Several retrospective and observational studies suggest the efficacy of this switch of TNF blocking agents. One recent randomised controlled trial supports this regimen (category B, D evidence [211] [212] [213] [214] [215] ). Observational data suggest the possibility that primary nonresponding patients are less likely to respond to a second TNF blocking agent. Patients who have not tolerated one TNF blocking agent may respond to a second but are also less likely to tolerate a second TNF blocking agent (category B, D evidence 200 208 209 ). The optimal treatment of patients not responding to TNF blockers remains to be determined (category B evidence 116 161 166 170 ).
2009 Update: Patients with high or moderate disease activity at baseline can respond well to TNF blocking agents (category C evidence 216 217 ). Golimumab (approved in Canada and USA) has demonstrated similar efficacy in clinical trials as other anti-TNF agents in improving signs and symptoms of patients with RA. 218 219 More extensive long-term safety data are needed to establish its place in the TNF blocking agent armamentarium.
Structural changes
TNFa blocking agents slow and/or inhibit radiographic progression in RA, even in some patients without a clinical response (category A evidence 220 221 ). Better clinical and radiological outcomes are achieved when TNFa blocking agents are used in combination with a traditional DMARD (category A evidence 222 ).
Pharmacoeconomic data
Evidence has become available that TNF blocking agents are cost effective from a societal perspective, although this is highly dependent upon the specific circumstances of the analysis and the society in which the analysis is done (category B evidence 106 223-226 ).
Juvenile idiopathic arthritis (JIA) Dosing and time to response
TNFa blocking agents, when given up to the maximum approved dosing regimens for polyarticular JIA, usually lead to an early significant, documentable improvement in symptoms, signs and/or laboratory parameters.
Comparing TNFa blocking agents in JIA Etanercept appears less effective in patients with systemic-onset JIA than in patients with other forms of JIA, There are no prospective studies in children less than 4 years of age; however, some observational registry data suggest comparable efficacy and safety in JIA not of the systemic-onset subtype, As for other subtypes of JIA, there is no evidence that any one TNFa blocking agent should be used before another one can be tried, just as there is no evidence that any TNF blocker is more effective than any other. In JIA-associated uveitis, adalimumab and infliximab appear to be effective more often than etanercept.
Structural changes in JIA
TNFa inhibition contributes to restoration of growth velocity in children whose JIA-associated inflammation is controlled. Bone density improves after treatment with TNFa blocking agents even in patients who have incomplete disease control.
Psoriatic arthritis (PsA) 226 231 ). A recent meta-analysis of randomised trials suggests that the efficacy of TNF blocking antibodies may be better than that of soluble receptor with respect to skin manifestations (category C evidence 235 ).
Dosing and time to response
2009 Update: Improvement of signs and symptoms, function and QoL occurs within 12 weeks. Some patients continue to improve to week 24. For etanercept, 100 mg/week was more effective than 50 mg/week for skin but not joint manifestations (category D evidence 236 ).
Comparing TNFa blocking agents in PsA
Preliminary data suggest that one can sometimes achieve benefit for PsA-related joint and skin signs and symptoms by switching to a different TNFa blocking agent, even if efficacy from a previous anti-TNF agent was never achieved (category C evidence 237 ).
Structural changes in PsA
Durability of clinical efficacy and radiographic data at 2 years in PsA has been demonstrated with etanercept, infliximab and adalimumab (category A, B, C evidence 232 234 236 
Ankylosing spondylitis (AS)
In clinical trials, improvement in signs and symptoms was seen after TNF blocking agents, using patient-reported outcomes (BASDAI, BASFI, patient global VAS, SF-36, spinal mobility measures, peripheral arthritis, enthesitis and acute phase reactants (category A, B, D evidence [239] [240] [241] [242] [243] ). Both infliximab and adalimumab are efficacious in active inflammatory bowel disease, which can be associated with AS.
2009 Update: Two recent placebo-controlled trials have shown significant efficacy in signs and symptoms in patients with non-radiographic axial spondyloarthritis (category A, D evidence 238 242 ) and according to the Assessment of Spondylo-Arthritis International Society (ASAS) axial criteria (category A evidence 244 ). There is evidence that the incidence of uveitis flares is reduced when patients are treated with TNF blocking agents (category B, C, D evidence [245] [246] [247] ). Regular treatment with infliximab was more effective than ''on demand'' treatment for AS (category A evidence 248 ). Observational studies indicate that switching to a second TNF blocking agent may be effective (category C, D evidence 237 ). There is no evidence that any TNFa blocking agent is more effective than any other. No dose-ranging studies have been done with any of these drugs.
The ASAS has published recommendations for the use of TNFa blocking agents in AS (category A evidence 244 ).
Dosing
The approved doses of TNF blocking agents for treatment of AS are 5 mg/kg infliximab intravenously every 6-8 weeks after induction, subcutaneous etanercept, 25 mg twice a week or 50 mg once a week, 50 mg subcutaneous golimumab monthly and 40 mg adalimumab subcutaneously every other week (category A, B evidence [249] [250] [251] ; category D evidence 214 217 218 ).
Time to response
A reduction in signs and symptoms, and improvement in function and QoL will usually be seen by 6-12 weeks in response to treatment with a TNFa blocking agent. Response may be delayed for up to a year (category D evidence 252 ).
Comparing TNFa blocking agents in AS
There is no evidence that any TNF blocking agent is more effective than any other (category A, B, D evidence 186-193 239 240-242 243 ). 
Persistence in AS
Structural changes
Several studies have shown that active inflammation of the sacroiliac joints and spine, as shown by MRI or radiograph, is significantly reduced for up to 3 years by adalimumab, etanercept and infliximab (category A evidence 240 242 250 ; category D evidence 251 ). Inhibition of new bone formation when using TNF blocking agents has not been demonstrated radiographically (category A, C evidence 241 242 ).
Pharmacoeconomic data in AS
The use of TNF blocking agents reduces the indirect costs of AS (category D evidence 256 ). Appendix 3 provides a reference listing of other conditions in which TNFa blocking agents have been used.
Safety (arranged alphabetically)
General reviews of TNFa blocking agent safety have been published (category B, C evidence 107 257-259 ).
Autoimmune-like syndromes
Antiphospholipid and lupus-like syndromes have occurred in both adult and paediatric patients during treatment with TNF blocking agents. Autoantibody formation is common after TNF blocking agent therapy (eg, antinuclear antibodies), but clinical syndromes associated with these antibodies are rare (category C evidence [260] [261] [262] ).
Cardiovascular
Treatment of non-RA patients with advanced chronic heart failure with TNF blocking therapy was associated with greater morbidity/mortality (infliximab) or lack of efficacy (etanercept). Studies that examined the risk of heart failure in patients with RA treated with TNFa blocking agents have shown inconsistent results (category B evidence [263] [264] [265] ). 2009 Update: The effect of TNF blocking agents on lipids is controversial (category D evidence [266] [267] [268] [269] [270] [271] [272] ). Several studies showed decreased cardiovascular events (myocardial infarction, stroke or transient ischaemic attack) (category D evidence 273 274 ).
Haematological
Rare instances of pancytopenia and aplastic anaemia have been reported (category A, C evidence 275 ). If haematological adverse events occur, TNFa blocking agents should be stopped and patients evaluated for evidence of other underlying disease or association with concomitant drugs.
Transaminase elevation
Rises in liver function tests have been seen in patients treated with adalimumab, infliximab or etanercept, with ALT-AST raised in 3.5-17.6% and increases of these liver enzymes more than twice the upper limit of normal in up to 2.1% (category D evidence 276 ). The use of concomitant drugs and other clinical conditions confound the interpretation of this observation (FDA; category B, C evidence [277] [278] [279] [280] [281] [282] [283] [284] [285] ). The follow-up and monitoring for increases in liver function test should be governed by the patient's concomitant drugs, conditions and patient-related risk factors. Worsening of alcoholic hepatitis has been seen in patients receiving TNF blocking agents (category D evidence 276 ).
Infections
Tuberculosis (TB)
An increased susceptibility to TB or reactivation of latent TB has been reported for all TNFa blocking agents. The risk of TB is also increased by the use of corticosteroids. The clinical manifestations of active TB may be atypical in patients treated with TNFa blocking agents (eg, miliary or extrapulmonary presentations) as has been seen with other immunocompromised patients (category C evidence [286] [287] [288] [289] ). There have been more reported cases of reactivation of latent TB as a proportion of the total number treated in patients using infliximab and adalimumab than in those using etanercept (category C evidence [290] [291] [292] [293] ). This may be due, in part, to differences in mechanism of action, biology or kinetics as compared with the soluble receptor (category D evidence 287 289 292 ) but may also be, in part, because populations treated with the various TNFa blocking agents differ (eg, higher background rates of TB in some countries) and the data come from registries and voluntary reporting systems. No head-tohead comparisons among TNF blocking agents have been carried out and thus no definitive data on comparisons between these agents are available for the incidence of reactivation of latent TB.
In a recent survey, done among infectious disease specialists in the United States (an area of low TB prevalence), only 35% of mycobacterial infections among TNF blocking agent users were M tuberculosis. M avium was as frequently found as M tuberculosis and multiple other non-tuberculous mycobacterial infections accounted for the rest of the mycobacterial infections (category C evidence 294 ). Screening of patients about to start TNFa blocking agents has reduced the risk of reactivating latent TB for patients treated with these agents (category B evidence [295] [296] [297] ). Every patient should be evaluated for the possibility of latent TB, including a history that should comprise seeking a history of prior exposure, prior drug addiction or active drug addiction, HIV infection, birth or extended living in a region of high TB prevalence and a history of working or living in TB high-risk settings such as jails, homeless shelters and drug rehabilitation centres (category B evidence 298 ; category D evidence 299 ). In addition, physical examination and screening tests such as tuberculin skin tests (TSTs) and chest radiographs should be carried out before TNFa blocking agent therapy is started, according to local recommendations (category B, C, D evidence 257 258 287 290 293 296 297 ). The TST is a diagnostic aid, and false-negative results can occur in the setting of immune suppression (eg, HIV, renal dialysis, corticosteroid use and RA) (category C evidence 300 ). The TST can also be falsely positive owing to prior BCG vaccination. New blood-based diagnostic assays (interferon c release assays) have been developed using TB-specific antigens. These tests (Quantiferon-Gold and T-Spot TB) have greater specificity for latent TB infection than does the TST, and therefore might provide a useful tool in evaluating people for latent TB, particularly those with history of BCG vaccination. It should be noted that false-negative results and indeterminate results also occur with the interferon c release assays (category C evidence 301 302 ). The precise role of these tests in diagnosing latent TB in patients with rheumatoid disease continues to be studied (category C evidence 302 ). Continued vigilance is required to detect reactivation of latent TB or acquisition of new cases.
In areas of high TB prevalence (ie, high-risk populations or in the event of potential TB exposure) repeat testing should be considered (category C evidence [303] [304] [305] [306] ). In treating latent TB, the optimal time frame between starting preventive treatment for latent TB infection and starting TNFa blocking agents is unknown. Given the low numbers of bacilli present in latent TB infection, it is likely that waiting long time periods between initiating preventive treatment and TNF blockade is unnecessary. While there are no prospective trials assessing this question, observational data from Spain suggest that initiating isoniazid treatment 1 month before TNF blockade substantially decreases the risk of latent TB reactivation (category C evidence 296 306 ). Before starting preventive anti-TB treatment in accordance with local guidelines, consultation with an infectious disease specialist should be considered.
2009 Update: There are case reports of reinitiation of TNF blocking agents after successful completion of full course antituberculosis treatment (category C evidence 307 ).
Other opportunistic infections
Other opportunistic infections have been reported in patients treated with TNFa blocking agents (category C evidence [308] [309] [310] [311] [312] [313] A British registry study found that the rate of intracellular infections among patients with RA treated with TNFa blocking agents was 200/100 000, and significantly higher than in similar patients treated with DMARDs or corticosteroids (category C, D evidence 289 291 293 ).
Bacterial infections
Serious bacterial infections (usually defined as bacterial infections requiring intravenous antibiotics or hospitalisation) have also been seen in patients receiving TNFa blocking agents at rates between 0.07 and 0.09/patient-year compared with 0.01-0.06/patient-year in controls using other DMARDs (category C evidence [314] [315] [316] ). Risk ratios of 1-3 were documented. TNFa blocking agents should not be administered when serious infections and/or opportunistic infections occur, including septic arthritis, infected prostheses, acute abscess, osteomyelitis, sepsis, systemic fungal infections and listeriosis (category C evidence 4 5 161 205 257-259 308-312 314-316 318 ). Treatment with TNFa blocking agents in such patients may be resumed if the infections have been treated adequately (category D evidence; FDA 259 287-289 298 319 ). Other studies indicate that serious infections in certain sites are more common when using TNFa blocking agents, such as the skin, soft tissues and joints, and the risk may be highest during the first 6 months of treatment and possibly increased further in elderly patients. (category C evidence 315 ; category D evidence 320 ). The possible contribution of previous or concomitant corticosteroids to increasing the risk of infection should always be considered (category B evidence 207 315 316 ).
2009 Update: Biological agents and high-dose corticosteroid affect acute phase reactions (eg, erythrocyte sedimentation rate, C-reactive protein) irrespective of the cause of the inflammation. Therefore care needs to be exercised to help diagnose infection in the presence of these agents (category C evidence 321 322 ). The incidence of other bacterial infections (not designated as serious) may be increased when using TNFa blocking agents (relative risk 2.3-3.0, 95% confidence interval (CI) 1.4 to 5.1) (category C evidence 314 ). The incidence of serious infections is approximately doubled when IL1ra or abatacept is used with any of the TNFa blockers in combination (category A evidence; FDA 36 37 113 258 259 ). The use of two biological agents in combination is not recommended.
Viral infections
Hepatitis: Patients should be screened for viral hepatitis before TNFa blocking agent initiation, as the long-term safety of TNFa blocking agents in patients with chronic viral hepatitis (hepatitis B and C) is not known. In patients with hepatitis C and RA, several observational studies in infected patients have shown no increased incidence of toxicity (eg, raised liver function tests or viral load) associated with TNFa blocking agent therapy. Interestingly, one reported controlled trial of etanercept given adjunctively to standard anti-HCV therapy was associated with significant improvement in liver enzymes, viral load and symptoms (category C, D evidence 278 279 285 ). In hepatitis B, patients treated with all three TNFa blocking agents have experienced increased symptoms, worsening of viral load and in some cases hepatic failure especially after stopping the TNFa blocking agents (category C, D evidence 277 285 ). As a result, specific warnings about hepatitis B reactivation have been added to the US label by the FDA. TNFa blocking agents should not be used in patients with known hepatitis B infection; in the event that hepatitis B infection is discovered during use of TNFa blocking agents, prophylactic antiviral therapy can be employed (category C evidence 323 ). 2009 Update: A recent observational study reported a small increase risk of H zoster with monoclonal antibodies, while other studies did not report an increased risk (category B, D evidence 217 219 321 ).
Vaccinations
TNFa blocking agents do not usually adversely effect the development of protective antibodies after vaccination with influenza or polysaccharide pneumococcal vaccine, although there is a small decrease in the prevalence of adequate protection and a decrease in the titre of response, especially in combination with MTX (category A, B evidence [324] [325] [326] ). Vaccination with live attenuated vaccines (eg, nasal flu vaccine, BCG, yellow fever, herpes zoster) is not recommended.
Injection site/infusion reactions
In placebo-controlled trials, injection site reactions, most of which were mild to moderate (but some of which resulted in drug discontinuation) were more common with subcutaneously administered TNFa blocking agents than with placebo (category B evidence 4 109-112 115 116 160-162 166 167 190 257 ). One study indicates that human anti-chimeric antibodies against infliximab were associated with decreased response and increased infusion reactions (category C evidence 327 ). Acute reactions after infliximab or adalimumab administration are uncommon and are usually mild to moderate, but may, rarely, be serious (category A evidence 4 110 161 166 193 219 226 ; category B, C evidence 328 ). In most instances, infusion reactions can be treated by the use of corticosteroids or antihistamines, or by slowing the infusion rate (category B, C evidence 322 327 ).
Malignancies
The incidence of lymphoma is increased in chronic inflammatory diseases such as RA. This increase is associated with high disease activity (category C evidence 329 330 ). In most studies the risk for lymphoma (especially non-Hodgkin's lymphoma) is increased two-to fivefold in patients with RA as compared with the general population (category B evidence [331] [332] [333] [334] [335] . A similar risk is seen in patients with RA who have received TNFa blocking agent therapy (category B, C evidence 259 329 333 334 ). It is unclear if the risk is increased (category A, B evidence 336 337 ). While two meta-analyses of anti-TNF therapies (with infliximab and adalimumab) report a higher rate of solid malignancies, including skin, (category A, C evidence 338 339 ) several other large observational databases and a case-control study did not demonstrate an increased incidence of solid tumours in patients receiving TNFa blocking agent compared with matched controls (category B, C evidence [340] [341] [342] [343] [344] ). 2009 Update: Further studies found no increased risk of solid tumours in analyses of the same data wherein positive associations were previously found (category A, B, C evidence 345 346 ). Neither the duration of treatment nor the duration of follow-up were associated with an increased risk of cancer during the first 5 years of treatment (category B evidence 335 345 ). The evidence for an increased incidence of non-melanotic skin cancers associated with TNF blocking agents is conflicting (category B evidence 345 ). In patients at risk for malignancies (eg, smokers) or in patients with COPD, there may be an increased risk of lung cancers. In a trial of patients with COPD assigned to infliximab versus placebo, nine developed lung cancers during the trial and another four lung cancers were found during open-label followup (category A evidence 341 342 ). Lung cancer seems to be increased in RA, although whether this is owing to disease activity or confounding factors is not known (category C evidence 341 342 ). In a study of Wegener's granulomatosis, the use of etanercept with cyclophosphamide was associated with six solid malignancies versus none in the cyclophosphamide placebo group (category A evidence 343 ). The concomitant use of azathioprine with infliximab in adolescents has been associated with the occurrence of rare hepatosplenic lymphomas (category C evidence, FDA). It is not currently known if TNF blockade worsens an underlying malignancy or increases the risk of recurrence (category B evidence 344 346 ). Vigilance for the occurrence of lymphomas and other malignancies (including recurrence of solid tumours) remains appropriate in patients treated with TNFa blocking agents.
Neurological diseases
Rare instances of central and peripheral demyelinating syndromes including Guillain-Barré syndrome have been reported in patients using TNFa blocking agents (category C evidence 347 ). In some cases, but not all, these syndromes have improved after withdrawal of TNFa blocking therapy and steroids were given. Accordingly, TNFa blocking therapy should not be given to patients with a history of demyelinating disease or optic neuritis (category D evidence [348] [349] [350] [351] [352] ).
Risks during pregnancy
The safety of anti-TNF therapy during pregnancy is unknown. Experts disagree about whether TNF blocking agents should be stopped when pregnancy is being considered or whether they can be continued throughout pregnancy. Some studies found no increased fetal loss or miscarriages when using TNF blocking agents, while one recent study did find an increased rate of miscarriages (category D evidence [353] [354] [355] . A rare combination of congenital abnormalities (VACTERL-vertebral abnormalities, anal atresia, cardiac defect, tracheo-oesophageal, renal and limb abnormalities) and partial VACTERL defect have been reported rarely although the risk and causality is unclear (category C evidence 356 ).
Pulmonary
Rare instances of acute, severe and sometimes fatal interstitial lung disease have been reported in patients using TNFa blocking agents (category C evidence 357 ).
Consensus statement
Skin disease
2009 Update: Cases of psoriasis, psoriaform lesions or exacerbation of psoriasis have been reported when using all TNF blocking agents. In some cases, switching TNF blocking agents allowed continuation of treatment without recrudescence of skin lesions (category D evidence [358] [359] [360] [361] . Additionally rare cases of Stevens-Johnson syndrome, digital vasculitis, erythema multiforme, toxic epidermal necrolysis granulomatous reactions in skin and lungs have been noted (category D evidence [362] [363] [364] ).
Summary
TNFa blocking agents are effective DMARDs and are a major advance in the treatment of RA, PsA, AS, JIA and anterior uveitis complicating JIA. Their use is expanding to other rheumatic diseases. Studies in selected areas of efficacy, toxicity and general use of TNFa blocking agents are needed to help define further the most appropriate use of these agents. Further considerations when using TNFa blocking agents in these diseases are the balancing of efficacy, toxicity and cost. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents. 365 ). Efalizumab is a humanised monoclonal antibody to the CD11 subunit of LFA-1. It has been removed from the market after cases of progressive multifocal leukoencephalopathy.
OTHER BIOLOGICAL AGENTS
Ustekinumab is an inhibitor of IL12 and 23 which acts in both the TH17 and TH1 pathways of inflammation and is approved for the treatment of psoriasis, and is given at 0, 4 and then every 12 weeks subcutaneously (category A evidence 366 ). A phase 2 study of patients with PsA, dosed weekly for 4 weeks, showed improvement in the signs and symptoms of PsA at the 12-week primary end point (category A evidence 367 ).
CONCLUSION
The treatment of RA and other rheumatic diseases and conditions of altered immunoreactivity has changed dramatically for the better since the introduction of biological agents into the armamentarium of the treating physician. It is hoped that this consensus statement will provide guidance to the clinician in his/her efforts to improve the quality of life of patients with these conditions. In addition, this consensus statement should provide evidence-based support for the selection of agents and justification for their use.
APPENDICES: CATEGORIES OF EVIDENCE
c Category A evidence: based on evidence from at least one randomised controlled trial or meta-analyses of randomised controlled trials. Also includes reviews if these contain category A references.
c Category B evidence: based on evidence from at least one controlled trial without randomisation or at least one other type of experimental study, or on extrapolated recommendations from randomised controlled trials or meta-analyses.
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